Application of delaviridine
The invention discloses application of delaviridine, particularly relates to application of delaviridine in resisting mycobacterium tuberculosis, and relates to the technical field of medicines, in particular to application of delaviridine, which provides a novel medicine for resisting mycobacterium tuberculosis. The delaviridine is researched and found for the first time to have a human macrophage level anti-tuberculosis effect and have a good clinical application value..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 12. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
BI JING [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-12, Last update posted on www.tib.eu: 2024-03-18, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
CN117379430 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001032542 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001032542 | ||
| 003 | DE-627 | ||
| 005 | 20240322141023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001032542 | ||
| 035 | |a (EPA)CN117379430 | ||
| 035 | |a (EPA)89471312 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a BI JING |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of delaviridine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-12, Last update posted on www.tib.eu: 2024-03-18, Last updated: 2024-03-22 | ||
| 520 | |a The invention discloses application of delaviridine, particularly relates to application of delaviridine in resisting mycobacterium tuberculosis, and relates to the technical field of medicines, in particular to application of delaviridine, which provides a novel medicine for resisting mycobacterium tuberculosis. The delaviridine is researched and found for the first time to have a human macrophage level anti-tuberculosis effect and have a good clinical application value. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a GUO QINGLONG |4 aut | |
| 700 | 0 | |a ZHANG GUOLIANG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 12. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89471312/publication/CN117379430A1?q=CN117379430 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 01 | ||